Log in

NASDAQ:TCON - TRACON Pharmaceuticals Stock Price, Forecast & News

$3.81
-0.22 (-5.46 %)
(As of 02/23/2020 04:00 PM ET)
Today's Range
$3.77
Now: $3.81
$4.05
50-Day Range
$2.40
MA: $3.68
$4.40
52-Week Range
$2.07
Now: $3.81
$17.30
Volume267,394 shs
Average Volume380,710 shs
Market Capitalization$11.96 million
P/E RatioN/A
Dividend YieldN/A
Beta2.01
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TCON
CUSIPN/A
Phone858-550-0780

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3 million
Book Value$7.18 per share

Profitability

Net Income$-34,960,000.00

Miscellaneous

Employees26
Market Cap$11.96 million
Next Earnings Date2/27/2020 (Confirmed)
OptionableNot Optionable

Receive TCON News and Ratings via Email

Sign-up to receive the latest news and ratings for TCON and its competitors with MarketBeat's FREE daily newsletter.


TRACON Pharmaceuticals (NASDAQ:TCON) Frequently Asked Questions

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals Inc (NASDAQ:TCON) posted its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.20) by $0.03. View TRACON Pharmaceuticals' Earnings History.

When is TRACON Pharmaceuticals' next earnings date?

TRACON Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for TRACON Pharmaceuticals.

How can I listen to TRACON Pharmaceuticals' earnings call?

TRACON Pharmaceuticals will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for TCON?

3 brokerages have issued 1-year price targets for TRACON Pharmaceuticals' shares. Their forecasts range from $7.00 to $18.00. On average, they anticipate TRACON Pharmaceuticals' share price to reach $12.50 in the next twelve months. This suggests a possible upside of 228.1% from the stock's current price. View Analyst Price Targets for TRACON Pharmaceuticals.

What is the consensus analysts' recommendation for TRACON Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TRACON Pharmaceuticals.

Has TRACON Pharmaceuticals been receiving favorable news coverage?

Media stories about TCON stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TRACON Pharmaceuticals earned a news impact score of -2.4 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for TRACON Pharmaceuticals.

Are investors shorting TRACON Pharmaceuticals?

TRACON Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 71,300 shares, an increase of 30.1% from the January 15th total of 54,800 shares. Based on an average trading volume of 462,000 shares, the short-interest ratio is currently 0.2 days. Currently, 2.1% of the shares of the stock are sold short. View TRACON Pharmaceuticals' Current Options Chain.

Who are some of TRACON Pharmaceuticals' key competitors?

What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include SCYNEXIS (SCYX), Verastem (VSTM), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Opko Health (OPK), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), MEI Pharma (MEIP), Progenics Pharmaceuticals (PGNX) and Catalyst Pharmaceuticals (CPRX).

Who are TRACON Pharmaceuticals' key executives?

TRACON Pharmaceuticals' management team includes the folowing people:
  • Dr. Charles P. Theuer, CEO, Pres, Principal Financial Officer, Principal Accounting Officer & Director (Age 55)
  • Mr. Scott B. Brown, VP & Head of Fin.
  • Dr. Sharon Real, Exec. VP of Product Devel. (Age 55)
  • Ms. Bonne Adams, Exec. VP of Clinical Operations (Age 42)
  • Ms. Suzy Benedict, Sr. VP of Regulatory Affairs

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an initial public offering on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

Who are TRACON Pharmaceuticals' major shareholders?

TRACON Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (11.04%), Renaissance Technologies LLC (4.83%) and Puissance Capital Management LP (2.42%). Company insiders that own TRACON Pharmaceuticals stock include Charles Theuer, Cross-Border Opportu Puissance, Enterprise Associates 14 New and Mark C Wiggins. View Institutional Ownership Trends for TRACON Pharmaceuticals.

Which institutional investors are selling TRACON Pharmaceuticals stock?

TCON stock was sold by a variety of institutional investors in the last quarter, including Puissance Capital Management LP, NEA Management Company LLC and Renaissance Technologies LLC. View Insider Buying and Selling for TRACON Pharmaceuticals.

How do I buy shares of TRACON Pharmaceuticals?

Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is TRACON Pharmaceuticals' stock price today?

One share of TCON stock can currently be purchased for approximately $3.81.

How big of a company is TRACON Pharmaceuticals?

TRACON Pharmaceuticals has a market capitalization of $11.96 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-34,960,000.00 in net income (profit) each year or ($13.00) on an earnings per share basis. TRACON Pharmaceuticals employs 26 workers across the globe.View Additional Information About TRACON Pharmaceuticals.

What is TRACON Pharmaceuticals' official website?

The official website for TRACON Pharmaceuticals is http://www.traconpharma.com/.

How can I contact TRACON Pharmaceuticals?

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at 858-550-0780 or via email at [email protected]


MarketBeat Community Rating for TRACON Pharmaceuticals (NASDAQ TCON)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  226 (Vote Outperform)
Underperform Votes:  183 (Vote Underperform)
Total Votes:  409
MarketBeat's community ratings are surveys of what our community members think about TRACON Pharmaceuticals and other stocks. Vote "Outperform" if you believe TCON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCON will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Featured Article: Do You Need a Fiduciary?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel